Scientific Sessions 2024  /  Circulation: Innovation in Cardiovascular Science and Medicine  /  Blinded Withdrawal of Long-term Randomized Treatment with Empagliflozin or Placebo in Patients With Heart Failure
Logo

American Heart Association

  2
  0

Final ID:

Blinded Withdrawal of Long-term Randomized Treatment with Empagliflozin or Placebo in Patients With Heart Failure

  • Packer, Milton  ( BAYLOR HEART AND VASCULAR INSTITUTE , Dallas , Texas , United States )
    • Author Disclosures:
    Milton Packer: DO have relevant financial relationships ; Consultant:89 bio:Past (completed) ; Consultant:Regeneron:Active (exists now) ; Consultant:Casana:Active (exists now) ; Consultant:Caladrius:Past (completed) ; Consultant:Boehringer Ingelheim:Past (completed) ; Consultant:Biopeutics:Active (exists now) ; Consultant:Altimmune:Active (exists now) ; Consultant:Attralus:Active (exists now) ; Consultant:Medtronic:Past (completed) ; Consultant:ARMGO:Active (exists now) ; Consultant:Ardelyx:Past (completed) ; Consultant:Lilly:Active (exists now) ; Consultant:Alnylam:Past (completed) ; Consultant:Imara:Past (completed) ; Consultant:Actavis:Past (completed)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Circulation: Innovation in Cardiovascular Science and Medicine

Sunday, 11/17/2024 , 03:30PM - 04:45PM

Cardiovascular Seminar

More abstracts on this topic:
Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients with Heart Failure with Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF Trial

Kosiborod Mikhail

Hypertrophic Cardiomyopathy

Day Sharlene

More abstracts from these authors:
In-Depth: SUMMIT: Tirzepatide for Patients With Heart Failure With Preserved Ejection Fraction and Obesity: the SUMMIT Trial

Packer Milton

Tirzepatide for Patients With Heart Failure With Preserved Ejection Fraction and Obesity: the SUMMIT Trial

Packer Milton

You have to be authorized to contact abstract author. Please, Login
Not Available